News

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering.
Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding.. Caris Life Sciences has now raised $1.86 billion in capital since 2018.
Caris Life Sciences will trade its stock under the ticker CAI. What is the IPO price for CAI? CAI shares were priced at $21, above their previously planned range.
For most medtech startups, the dream of raising a billion dollars is nothing but a castle in the air. | The new funding values Caris at more than $7.8 billion and brings its total external funding ...